Celyad Oncology SA (NASDAQ:CYAD)

0.9997
BATS BZX Real-Time Price
As of Dec 02
 0.00 / 0.00%
Today’s Change
0.95
Today|||52-Week Range
5.10
-72.69%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$22.6M

Company Description

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Contact Information

Celyad Oncology SA
Axis Business Park
Mont-Saint-Guibert Walloon Region 1435
P:(210) 039-4100
Investor Relations:

Employees

Shareholders

Other institutional0.32%
Mutual fund holders0.01%
Individual stakeholders--

Top Executives

Michel E. LussierChief Executive Officer & Executive Director
David GeorgesVice President-Finance & Administration
Eytan BremanDirector-Research & Development
Frederic LehmannVP-Clinical Development & Medical Affairs
David GilhamChief Scientific Officer